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passaged for a prolonged period of time in culture, undergoes a
non-clonal change reflected in lower ERK activity, increased p38
activity and a dormant/quiescent phenotype in vivo (D-HEp3).
When inoculated in vivo 80% of D-HEp3 cells rapidly arrest
in G0/G1 by day 6 after inoculation and remain dormant for sev-
eral months. We also found that activated p38 establishes a neg-
ative feedback loop to ERK and that blocking of p38 by genetic
or pharmacological inhibitors restores ERK activation and inter-
rupts tumor dormancy in vivo. These studies implicated high
p38 activity in the induction of dormancy in vivo. While p38 is
known to induce growth arrest and/or apoptosis, there is also
evidence indicating that in some instances, p38 signaling can
promote cell survival. However, knowledge of the proximal tar-
gets of p38 that underlie the p38-dependent dormancy program,
in particular the balance between cell proliferation and cell
death, have not been identified. We now show that p38 regu-
lates the activation of the endoplasmic reticulum (ER)-stress
activated kinase PERK and expression of the ER chaperone BiP/
Grp78. Regulation by p38 of these pathways allows dormant
tumor cells to not only become dormant but also resist drug-
toxicity. Increased activation of the eIF2a kinase PERK, results
in upregulation of ATF4 and activation of GADD153 promoter.
RNAi and dominant negative expression studies revealed that
both BiP and PERK promote survival and drug-resistance of dor-
mant cells and that BiP upregulation prevents Bax activation.
Further, genetic experiments showed that activation of the
PERK-eIF2a pathway is important for the maintenance of dor-
mancy. We propose that stress-dependent activation of p38 that
results in BiP upregulation and PERK activation may represent a
novel growth arrest and survival mechanism that induces dor-
mancy and protects dormant tumor cells from stress-insults
such as chemotherapy.
doi:10.1016/j.ejcsup.2006.04.009
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Colorectal cancer is the second leading cause of cancer deaths in
western countries. Although inactivation of the APC and p53
tumor suppressor genes coupled with Kirsten-Ras oncogene acti-
vation contribute to colon carcinogenesis, simultaneous muta-
tion of these three genes is rare suggesting alternate genetic
pathways leading to colon tumorigenesis/progression. To iden-
tify novel genes that contribute to colon cancer development/
progression we ‘‘data-mined’’ genes aberrantly expressed in
colorectal cancer using SAGE and UniGene Cluster Expression
analysis and identified, a novel Scan domain-containing zinc fin-
ger protein (ZNF306) whose expression is elevated in colon can-
cer. RT-PCR analysis of resected colon cancers showed elevated
ZNF306 mRNA levels in two thirds of tumors compared with
paired adjacent non-malignant tissue. Stable expression of the
cloned ZNF 306 cDNA in HCT 116 colon cancer cells yielded
enhanced soft agar colony formation, anoikis resistance and
resistance to 5-flurouracil when compared with cells bearing
the empty vector. More importantly, orthotopic implantation of
ZNF306-overexpressing HCT 116 cells yielded large tumors in
100% of the mice compared with vector only-expressing cells
which produced smaller tumors with a lower penetrance (20%
of mice). Conversely, transduction of two independent colon
cancer cell lines with a-ZNF306 siRNA reduced mRNA levels,
diminished colony size and attenuated cell proliferation. Fur-
ther, in vivo delivery of neutral liposomal-encapsulated siRNA
targeting ZNF306 reduced orthotopic growth of HCT116-ZNF306
cells. Flag-tagged expressed ZNF306 was nuclear-localized and
since zinc finger-containing proteins recognize DNA site-specific
sequences, we hypothesized that ZNF306 is a transcription fac-
tor. Cyclic amplification and selection of targets (CAST-ing) using
a random oligonucleotide library identified the KRKGGGG nucle-
otide sequence as a putative DNA binding site. Expression profil-
ing studies revealed several candidate downstream targets of
ZNF306 including VEGF and integrin b4, implicated in angiogen-
esis and Ras/PI3-kinase signaling, respectively. Over-expression
of these two putative targets was confirmed by RT-PCR. Addi-
tionally, increased CD31 (endothelial cells) immunoreactivity in
the ZNF306-over-expressing orthotopic tumors indicated aug-
mented angiogenesis. Both genes contained ZNF306 binding
sites in their regulatory sequences and chromatin immunopre-
cipitation assays and EMSA, using an anti-ZNF306 antibody we
generated, demonstrated binding of the ZNF306 protein to its
recognition sequence (identified by CAST-ing) in the VEGF pro-
moter indicating this gene to be a direct target of ZNF306.
Immunohistochemistry employing the anti-ZNF306 antibody
showed increased ZNF306 protein in colon cancer tissues com-
pared with adjacent non-malignant mucosa. In conclusion, we
have discovered a novel zinc finger protein, ZNF306 that contrib-
utes to colon cancer progression in part by elevating VEGF and
integrin b4 expression. We propose that this gene product repre-
sents a key protein in an alternate genetic pathway leading to
colon cancer progression.
doi:10.1016/j.ejcsup.2006.04.010
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The urokinase-receptor (u-PAR) promotes the invasive and meta-
static phenotype and has been shown to be associated with early
relapse and poor prognosis in enumerous types of cancers. From
our and other studies we know that high u-PAR gene expression
in carcinoma cells is largely due to the transcriptional regulation
of the gene. We have characterized two cis-elements (152/135,
bound with an AP-2-like protein, Sp1, and Sp3; 190/171, bound
with AP-1-transcription factors) of the u-PAR promoter which are
decisive for diverse means of u-PAR-gene expression in highly
invasive colon cancer cells, among them being constitutive,
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